Abtract
Background
This study describes imaging features of diffuse intrinsic pontine glioma (DIPG) and correlates with overall survival (OS) and histone mutation status in the International DIPG Registry (IDIPGR).
Methods
Four hundred cases submitted to the IDIPGR with a local diagnosis of DIPG and baseline MRI were evaluated by consensus review of 2 neuroradiologists; 43 cases were excluded (inadequate imaging or alternative diagnoses). Agreement between reviewers, association with histone status, and univariable and multivariable analyses relative to OS were assessed.
Results
On univariable analysis imaging features significantly associated with worse OS included: extrapontine extension, larger size, enhancement, necrosis, diffusion restriction, and distant disease. On central review, 9.5% of patients were considered not to have DIPG. There was moderate mean agreement of MRI features between reviewers. On multivariable analysis, chemotherapy, age, and distant disease were predictors of OS. There was no difference in OS between wild-type and H3 mutated cases. The only imaging feature associated with histone status was the presence of ill-defined signal infiltrating pontine fibers.
Conclusions
Baseline imaging features are assessed in the IDIPGR. There was a 9.5% discordance in DIPG diagnosis between local and central review, demonstrating need for central imaging confirmation for prospective trials. Although several imaging features were significantly associated with OS (univariable), only age and distant disease were significant on multivariable analyses. There was limited association of imaging features with histone mutation status, although numbers are small and evaluation exploratory.
Keywords: diffuse midline glioma, DIPG, histone mutation, international DIPG registry, MRI
Key Points.
Detailed description of baseline MR imaging features currently evaluated in the IDIPGR.
Multiple imaging features correlated with OS.
There was limited correlation with H3K27M mutation status.
Importance of the Study.
This study represents a detailed description of baseline MR imaging features currently evaluated in the IDIPGR, which will serve as a guide for imaging definitions and a resource for future IDIPGR approved research projects. While some imaging features correlated with OS, there was more limited correlation with H3K27M mutation status (although numbers are small).
Brainstem tumors make up 10–20% of central nervous system tumors in children and are traditionally divided into tumors that are focal and well defined (20%) or diffuse (80%) on imaging.1,2 Prognosis for diffuse brainstem tumors has remained very poor.1 Recently, the discovery of recurrent somatic gain-of-function mutations leading to lysine 27 to methionine (p.Lys27Met,K27M) substitution in histone 3 (H3) variants (H3.3 and H3.1) in approximately 80% of diffuse brainstem tumors has transformed our understanding of their biology.3–5 Initial reports indicated patients with H3K27M-mutant tumors have a worse prognosis than wild-type (WT) diffuse brainstem tumors, despite similar histopathology (World Health Organization [WHO] grades II–IV astrocytomas).3,6 This has led the WHO to reclassify pediatric diffuse gliomas into a newly defined entity, “diffuse midline glioma, H3K27M–mutant,” which includes tumors of the brainstem, spinal cord, and thalami.7 The term “DIPG” remains relevant as a clinical-radiologic diagnosis encompassing diffuse tumors intrinsic to the pons, many (but not all) of which will be H3K27M-mutants.6 Despite these advances, imaging genomic correlations are few.6,8
Imaging is critical to establish a probable diagnosis of DIPG, define extent of disease, exclude other diagnoses, and guide biopsy when indicated.9 Prior studies have related imaging findings to survival with variable results.2,9–12 Part of this variability is likely related to differing imaging criteria for DIPG, different definitions for key imaging features, lack of standardization of sequence acquisition, small numbers of subjects, as well as inclusion of focal and exophytic tumors.13,14
In order to improve our understanding of these devastating tumors, we and our European colleagues have established multi-institutional registries.15,16 To date, the International DIPG Registry (IDIPGR) has enrolled 1032 patients from 115 participating institutions in 15 countries. Limited imaging results on 247 subjects in the IDIPGR cohort have been recently reported as part of a validation dataset of a prognostic model initially assessed in the European Society for Paediatric Oncology (SIOPE) DIPG cohort.17 The current study reports an analysis of the full imaging features available in the IDIPGR.
Materials and Methods
This study was approved by the scientific review board of the IDIPGR and the local institutional review board at Cincinnati Children’s Hospital Medical Center. Details of recruitment and structure of the IDIPGR have been described previously.15 All submitted cases as of July 2018 with centrally reviewed baseline MR imaging were eligible for inclusion. Clinical information included: age, sex, symptom duration, neurologic findings, treatment with any chemotherapy, treatment with radiotherapy, and duration of related symptoms before diagnosis.
Imaging Review
Imaging evaluation was performed blinded to clinical data, as previously described.15 MR imaging studies were reviewed by both registry neuroradiologists (26 and 25 years of post-fellowship clinical experience) utilizing a referenceable nomenclature. One reviewer would assess the case and fill out a standardized form. The second reviewer would then assess the case, referencing the form from the primary reviewer. Consensus opinion was utilized if there were discrepancies between reviewers and all imaging features were assessed and agreed upon by both reviewers. Imaging features were defined based in part on prior imaging studies of DIPG2,11–13,18–20 optimized for reproducibility by assessment of an initial 20 learning cases by both reviewers (subsequently reevaluated as part of the final imaging review process). For the last 30 evaluated subjects, imaging features were assessed by both reviewers independently to define interobserver variability. For the first 30 evaluated subjects, tumor and pons measurements were performed separately by both reviewers for purposes of defining interobserver variability. For the remainder, tumor and pons measurements were performed by one reviewer and checked by the other reviewer, and consensus measurements made if there were discrepancies.
Each case was categorized by the neuroradiology reviewers as: (i) characteristic DIPG by imaging appearance (arises from the pons, exhibits a diffuse pattern of involvement, and involves ≥50% of the pons)2,11; (ii) likely DIPG with some unusual features (most commonly large areas of necrosis or hemorrhage) but otherwise characteristic of DIPG; or (iii) non-DIPG, alternative diagnosis suspected (which were excluded from further analysis)20–22 (Supplementary 1). Excluded for the purposes of this study were cases in which there was secondary brainstem involvement by a tumor centered in the thalami, cerebral hemispheres, or cerebellar hemispheres.
Imaging features were visually evaluated (Supplementary 1) including: tumor size by linear measurement, pons dimension, extension, percent of pons involved (cross-sectional area on any cut over the pons, subjectively assessed), eccentric position, tumor margin, signal intensity, heterogeneity, localized T2 hypointensity,23 diffusion restriction, hemorrhage, enhancement characteristics, necrosis, tumor perfusion, spectroscopic features, hydrocephalus, and presence of distant noncontiguous disease (intracranial and intraspinal). Other imaging features were assessed in an exploratory manner to correlate with biologic data and were not part of the registry core imaging features described above (Supplementary 2). These included the presence of “stripes” (previously described by Castel et al)6 nonnecrotic T2 hyperintensity regions,19 as well as the presence of diffuse T2 fluid attenuated inversion recovery hypointensity within the tumor (a pattern recognized during our review of cases for this study). Quantitative analysis of diffusion, perfusion, and spectroscopy data was not undertaken in this study due to the limited and variable nature of the submitted sequences.
Histone Mutation Status
Subjects (n = 57) had biologic data from biopsy or autopsy. In addition to histologic diagnosis, genomic data were derived from whole genome sequencing, whole exome sequencing, RNA sequencing, or clinical genomics panels and mutation status of loci for H3F3A (H3.3), HIST1H3B (H3.1), or immunohistochemistry (IHC) assessment of histone mutation status by report supplied by each institution or through tissue re-staining. The IHC method utilizes a polyclonal mutant-specific antibody that recognizes the product of all H3K27M variants (including H3.3, H3.1, and others), a positive result visualized microscopically as strong nuclear staining of the tumor cells.18
Statistical Analysis
Univariable and multivariable analyses of imaging features, clinical data, and histone status relative to overall survival (OS) (diagnosis to death) were performed using Cox proportional hazards regression. Results were summarized for OS and histone status with a hazard ratio (HR) and an odds ratio (OR), respectively. Features with P < 0.05 in univariable analysis were chosen for multivariable analysis when applicable. Agreement between reviewers was assessed with concordance rates and kappa statistics for imaging features, and paired t-tests for quantitative data.
Results
Excluded Cases
A total of 400 cases with baseline imaging available as of September 2018 were reviewed. Of these, 43 (11%) were excluded from further analysis: 5 no baseline MRI, 22 nonpontine origin, and 16 with imaging features strongly suggestive of another diagnosis. These included well-defined exophytic tumors with marked enhancement (likely pilocytic, N = 7), localized, markedly diffusion restrictive, often eccentric tumors (presumed primitive neuroectodermal tumor, N = 5), diffuse or multifocal tumors with primarily hemispheric and thalamic involvement with secondary brainstem extension (N = 2), and lesions with ill-defined minimal signal (presumed nonneoplastic, N = 2) (Supplementary 1). Thus, 38/400 subjects (9.5%) with a local diagnosis of DIPG did not meet imaging criteria for DIPG based on central review.
Demographic, Clinical, and Imaging Details
Of the 357 patients with a clinical-radiologic diagnosis of DIPG, 197 were females, 160 males. Median age was 6.2 years (range, 1 mo‒27 y). N = 272 (76%) subjects received chemotherapy, and 336 (94%) radiotherapy (267 both; 61 only radiotherapy, 4 only chemotherapy, 12 neither, 8 radiotherapy—unknown chemotherapy status, 1 chemotherapy, unknown radiotherapy status, 4 unknown treatment status). Studies (n = 347) incorporated administration of a gadolinium-based contrast agent, 292 studies included diffusion sequences, 146 studies included gradient recalled echo (GRE) or susceptibility weighted imaging (SWI) sequences, 31 studies included perfusion imaging, and 88 studies included spectroscopy within the tumor. Baseline spine studies were available for review in 133 cases.
Interobserver Agreement
On central review, there was no significant difference in tumor measurements between reviewers (Table 1). There was a significant difference in anterior-posterior (AP) pontine measurements between reviewers with no significant difference in transverse (TR) pontine measurement (Table 1).
Table 1.
Interobserver agreement, tumor and pons measurements
Measurement | Mean Difference (mm) | Range | P |
---|---|---|---|
Tumor AP | 2.6 mm | 0–15 mm | 0.155 |
Tumor Trans | 3.7 mm | 0–17 mm | 0.604 |
Tumor CC | 2.5 mm | 0‒41 mm | 0.139 |
Pons AP | 1.8 mm | 0–6 mm | 0.0001 |
Pons Trans | 1.8 mm | 0–5 mm | 0.065 |
Using dichotomized MRI feature classifications, there was moderate mean agreement between reviewers (mean agreement rate, 0.838; mean kappa, 0.622), with some variability (Table 2).
Table 2.
Interobserver agreement of MRI feature classification*
Feature | N | Agreement Rate | Kappa (UW, Observed) | Kappa (max) |
---|---|---|---|---|
Tumor extension beyond pons/BP | 30 | 0.830 | 0.210 | 0.526 |
Tumor extension (raw) | 30 | 0.330 | NA | NA |
Tumor margins (well vs ill-defined) | 30 | 0.800 | NA | NA |
Tumor location (central vs eccentric) | 30 | 0.930 | 0.634 | 0.634 |
Tumor extent (contained vs exophytic) | 30 | 0.767 | 0.420 | 0.420 |
Tumor signal (T1/T2) | 30 | 1.000 | 1.000 | 1.000 |
T2 hypointensity | 30 | 0.533 | 0.110 | 0.237 |
Diffusion restriction | 18 | 0.778 | 0.517 | 0.753 |
Heterogeneity (any) | 30 | 1.000 | 1.000 | 1.000 |
Heterogeneity (raw) | 30 | 0.667 | NA | NA |
Hemorrhage | 30 | 0.933 | 0.634 | 0.634 |
Enhancement (yes vs no) | 29 | 0.897 | 0.731 | 0.910 |
Enhancement pattern | 29 | 0.758 | 0.638 | 0.774 |
Necrosis | 30 | 0.933 | 0.864 | 1.000 |
Spectroscopy Cho elevation | 7 | 0.570 | NA | NA |
Spectroscopy reduced NAA | 7 | 0.860 | NA | NA |
Spectroscopy lactate | 7 | 0.860 | NA | NA |
Hydrocephalus | 30 | 0.967 | 0.911 | 0.911 |
Non-DIPG | 30 | 0.967 | NA | NA |
Mean (dichotomized) | 0.838 | 0.622 | 0.733 |
*NA: some cell numbers too few for kappa calculation.
MRI Features of DIPG
A summary of the MRI features is given in Table 3: 11 had distant non-contiguous tumor at diagnosis (3.1%; 6.8% in those with spine imaging at baseline), including intracranial leptomeningeal (n = 5, 1.4%), spinal leptomeningeal (n = 5, 1.4%), subventricular24 (n = 2, 0.6%), cerebellar parenchymal (n = 1), spinal parenchymal (n = 1), non-contiguous midbrain and thalamus (n = 1). Four cases had mixed patterns. Of 133 subjects with baseline spine imaging, 4 (3%) had spinal distant disease (1 cervical cord, 3 leptomeningeal), with 2 (1.5%) as their only distant disease site. Overall, 6 (1.7%) cases had spinal and 8 (2.2%) had intracranial disseminated disease at diagnosis.
Table 3.
Baseline imaging characteristics in 357 DIPGs
Imaging Feature | N | % Cases* | Note |
---|---|---|---|
Tumor Extension | |||
No extension beyond pons | 15 | 4.2 | |
Cerebellum | 85 | 23.8 | |
Midbrain | 245 | 68.6 | |
Thalami | 25 | 7.0 | |
Medulla | 260 | 72.8 | |
Internal capsule | 24 | 6.7 | |
Brachium pontis | 284 | 79.6 | |
Extension beyond pons and BP | 319 | 89.4 | |
% pons involved | |||
1–33% | 1 | 0.3 | |
34–66% | 21 | 5.9 | |
67–100% | 335 | 93.8 | |
<50% | 3 | 0.8 | |
>50% | 354 | 99.2 | |
Tumor Morphology | |||
Margin (well-defined) | 15 | 4.2 | |
Eccentric | 50 | 14.0 | |
Exophytic | 229 | 64.1 | |
Heterogeneity (marked) | 54 | 15.1 | |
Atypical features but likely DIPG | 92 | 25.8 | |
Tumor Signal | |||
T1 hypointense/T2 hyperintense | 336 | 95.7 | 351 with both T1 and T2 sequences |
T2 hypointensity (any) | 189 | 53.2 | 2 missing T2 sequence |
Non-necrotic T2 hyperintensity (any) | 128 | 36.1 | 2 missing T2 sequence |
Stripes visible | 251 | 70.5 | 1 incomplete data |
Enhancement | |||
Enhancement (any) | 239 | 68.9 | of 347 that had contrast |
Homogeneous | 2 | 0.8 | of 239 that had enhancement |
Ring enhancement | 122 | 51.5 | of 239 that had enhancement |
Patchy enhancement | 162 | 67.4 | of 239 that had enhancement |
Patchy and ring enhancement | 46 | 19.2 | of 239 that had enhancement |
Diffusion/Hemorrhage/Necrosis | |||
Diffusion restriction (any) | 184 | 63.2 | of 291 with diffusion sequence |
Hemorrhage (any) | 102 | 28.6 | |
Hemorrhage (> minimal) | 40 | 11.2 | |
Hemorrhage (any, GRE/SWI) | 73 | 50.0 | of 146 with SWI or GRE sequence |
Hemorrhage (>minimal.,GRE/SWI) | 31 | 21.2 | of 146 with SWI or GRE sequence |
Necrosis (any) | 156 | 43.6 | |
Necrosis + ring enhancement | 118 | 34.0 | of 347 that had contrast |
Necrosis with no ring enhancement | 37 | 10.7 | of 347 that had contrast |
Spectroscopy | |||
NAA/Cr (decreased) | 66 | 75.0 | of 88 with spectroscopy |
Cho/Cr (increased) | 74 | 84.1 | of 88 with spectroscopy |
Cho/NAA (increased) | 75 | 85.2 | of 88 with spectroscopy |
mI/Cr (increased) | 34 | 41.0 | of 83 with assessable mI |
Lactate present | 56 | 64.4 | of 87 with assessable lactate |
Other Features | |||
Hydrocephalus | 79 | 22.1 | |
Subependymal signal | 78 | 21.8 | *see note |
Distant disease | 11 | 3.1 | of 357 cases |
Distant disease (spine available) | 9 | 6.8 | of 133 with spine imaging |
* 26 subjects with no hydrocephalus had subependymal signal, 52 subjects with hydrocephalus had subependymal signal.
MRI Features and Overall Survival
OS data were available for 351 cases (median survival, 10.9 mo; range, 0.1–100.5 mo, 1 alive at time of data collection). On univariable analyses, clinical and imaging features that significantly correlated with shorter OS included (Table 4): shorter symptom duration, no chemotherapy, tumor extension into the midbrain and/or beyond pons and brachium pontis, larger cranial-caudal (CC) tumor dimension, larger AP × CC tumor product, larger AP tumor/pons measurement ratio, presence of diffusion restriction, tumor enhancement or necrosis, and presence of distant disease at diagnosis. A full listing of assessed features is given in the Supplementary Material (Supplementary 3). On multivariable analysis shorter symptom duration and distant disease at diagnosis remained significantly correlated with shorter OS (Table 5).
Table 4.
Univariable analysis of imaging features and overall survival (significant findings)
Univariate | ||
---|---|---|
HR | P | |
Clinical | ||
Age (continuous) | 1.00 | 0.033 |
Age | 0.001 | |
Symptom duration | 0.018 | |
Chemotherapy | 0.46 | <0.001 |
Midbrain extension | 1.36 | 0.008 |
Extension Beyond Pons and BP | 1.64 | 0.002 |
Extension Beyond Pons | 2.15 | 0.001 |
AP Tumor dimension | 1.02 | 0.023 |
Trans Tumor dimension | 1.01 | 0.031 |
AP X Trans Tumor dimension | 1.00 | 0.029 |
CC Tumor dimension | 1.01 | 0.009 |
AP Tumor / AP pons ratio | 2.29 | 0.005 |
AP X TR Tumor > AP X TR Pons | 1.30 | 0.012 |
Enhancement (any) | 1.36 | 0.010 |
Ring enhancement vs non-enhancing | 1.45 | 0.007 |
Patchy enhancement vs non- enhancing | 1.44 | 0.005 |
Patchy and ring enhancement vs non-enhancing | 1.93 | 0.001 |
Diffusion restriction (any) | 1.46 | 0.003 |
Hemorrhage (any) | 1.22 | 0.098 |
Hemorrhage (GRE/SWI) | 1.43 | 0.028 |
Necrosis (any) | 1.47 | 0.0006 |
Necrosis + Ring Enhancement | 1.40 | 0.005 |
Necrosis with no Ring Enhancement | 1.48 | 0.034 |
Distant Disease | 2.95 | 0.0005 |
Distant Disease (spine available) | 2.64 | 0.0031 |
Table 5.
Multivariable analysis of clinical and imaging features and OS
Variable | HR | P |
---|---|---|
Age | 0.0187 | |
<3 | 0.76 | |
3–10 | 1.00 | |
10+ | 0.66 | |
Symptom duration | 0.1164 | |
<6 weeks | 1.00 | |
6–12 weeks | 0.78 | |
12–24 weeks | 0.76 | |
>24 weeks | 0.60 | |
Chemo | 0.45 | <0.0001 |
Extension beyond Pons or BP | 1.10 | 0.9247 |
AP Tumor dimension | 0.99 | 0.3246 |
Trans Tumor dimension | 1.00 | 0.8672 |
CC Tumor dimension | 1.01 | 0.1996 |
AP Tumor / AP pons ratio | 2.26 | 0.0631 |
Beyond Pons | 1.33 | 0.7807 |
Enhancement (any) | 1.21 | 0.2167 |
Heterogeneity (marked) | 0.94 | 0.7601 |
Necrosis | 1.21 | 0.1932 |
Distant Disease | 2.97 | 0.0021 |
*Diffusion status removed for missing >10%, AP x Trans and AP x CC for high correlation with AP, midbrain extension since it is included in the definition of extension beyond Pons or BP, extension beyond pons and brachium pontis due to correlation with extension beyond pons, enhancement subtypes due to correlation with enhancement, and hemorrhage with SWI or GRE sequences due to missing >10%).
Histone Status
As an exploratory analysis, 57 subjects with available histone mutation status (detailed above) were assessed: 17 had analysis by IHC (7 had only IHC for histone status) and 50 had genomic data. In those with genomic data available, 29 cases were H.3, 11 cases were H.1 mutated, and 10 were WT (Table 6). Because of the small numbers of subjects, histone status was pooled and classified as: H3 mutation positive (either IHC positive, HIST1H3B (H3.1) positive, orH3F3A (H3.3) positive], or WT (IHC negative, without H3.3 or H3.1 mutations on genomic assessment). Using this classification, there were 47 H3 mutation subjects and 10 WT subjects. There was no difference in OS between (i) H3 mutation and WT subjects (HR 0.97, P = 0.927) or between (ii) those with H3.3 or H3.1 histone status (HR 1.22 for H3.3, 1.0 for H3.1, P = 0.583), although numbers were small. Selected imaging features were correlated with H3 or WT mutation status (those that were correlated with OS, as well as those potentially related based upon prior published data).6 No imaging feature correlated with histone status (H3 vs WT or H3.3 vs H3.1; Table 6). The presence of “T2 stripes” was more prevalent in H3 tumors than WT tumors (OR 4.98, P = 0.03), and was seen more commonly in H3.1 tumors (90.9%) than H3.3 tumors (58.6%) (not statistically significant). Necrosis and enhancement were also more prevalent in H3.1 versus H3.3 tumors without attaining statistical significance (Table 6).
Table 6.
Imaging features and histone mutation status
Imaging—Genomic Analysis | Genomic Classification | Statistical Comparison | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
H3 | H3.1 | H3.3 | WT | H3 vs WT | H3.3 vs H3.1 | |||||||
Imaging Feature | (N = 47) | % | (N = 11) | % | (N = 29) | % | (N = 10) | % | OR | P | OR | P |
Extrapontine extension | 43 | 91.5 | 11 | 100 | 25 | 86.2 | 9 | 90 | 1.22 | 0.82 | 0.31 | 0.31 |
AP tumor dimension (mean) | 35.3 | 38.4 | 34.8 | 33.7 | 1.03 | 0.55 | 0.94 | 0.21 | ||||
AP Tumor/AP Pons (mean) | 0.988 | 0.998 | 0.992 | 1.045 | 0.12 | 0.29 | 0.75 | 0.90 | ||||
CC tumor (mean) | 42.3 | 46.5 | 41.1 | 39.0 | 1.03 | 0.37 | 0.95 | 0.15 | ||||
Eccentric | 14 | 29.8 | 2 | 18.2 | 9 | 31.0 | 1 | 10 | 3.82 | 0.22 | 2.03 | 0.42 |
Non-necrotic T2 hyperintensity | 17 | 36.2 | 6 | 54.5 | 7 | 24.1 | 3 | 30 | 1.45 | 0.62 | 0.32 | 0.12 |
T2 hypointensity | 28 | 59.6 | 7 | 63.6 | 16 | 55.2 | 6 | 60 | 0.98 | 0.98 | 0.63 | 0.70 |
Stripes present | 32 | 68.1 | 10 | 90.9 | 17 | 58.6 | 3 | 30 | 4.98 | 0.03 | 0.14 | 0.08 |
Enhancement | 38 | 80.9 | 10 | 90.9 | 22 | 75.9 | 10 | 100 | 0.29 | 0.19 | 0.31 | 0.31 |
Peripheral ring like enhancement | 22 | 46.8 | 6 | 54.5 | 14 | 48.3 | 7 | 70 | 0.59 | 0.49 | 1.17 | 0.84 |
Diffusion restriction present* | 27 | 60.0 | 6 | 54.5 | 18 | 64.3 | 7 | 70 | 0.64 | 0.56 | 1.50 | 0.58 |
Hemorrhage present | 21 | 44.7 | 5 | 45.5 | 13 | 44.8 | 4 | 40 | 0.79 | 1.21 | 0.97 | 0.98 |
Necrosis present | 27 | 57.4 | 8 | 72.7 | 17 | 58.6 | 7 | 70 | 0.58 | 0.47 | 0.53 | 0.41 |
*Two H3 had no diffusion imaging and one H3.3 had no diffusion imaging.
Discussion
DIPG Definition
We have described the imaging spectrum of DIPGs in a large number of subjects in a multi-institutional registry (IDIPGR), defined specific baseline imaging features and diagnostic criteria, assessed interobserver agreement related to the imaging features, and validated the utility of the imaging descriptors by correlating them with OS. In addition, we have preliminarily assessed the relationship of imaging features in these tumors to histone mutation status. Defining imaging criteria for DIPG and standardizing and validating a defined set of imaging features is an important component of the imaging core of the IDIPGR. These assessments can be used by registry-approved research in the future, and will provide the basis for further studies.15
The definition of DIPG is based on both clinical and radiologic features. The concept of “diffuse midline glioma” encompassing diffuse glial origin tumors of the spinal cord, brainstem, thalami, and other midline locations (associated with the H3K27M histone mutation) has been adopted by the WHO and incorporates most of those tumors previously identified as DIPG.7 DIPG as a general descriptor remains a highly useful clinical-radiologic classification based upon the common clinical presentation, age demographics, imaging appearance, and extensive prior literature related to DIPG, and could include both tumors with H3K27M mutation and WT tumors.
On imaging, DIPGs have previously been described as intrinsic, infiltrative diffuse pontine tumors, typically with brainstem expansion and involvement of 50% or greater of the pons.2 In this study we did include a small number of subjects (3/357, 0.8%), which involved <50% of the pons (classified as likely DIPG). Each had an imaging appearance that was otherwise compatible with DIPG and on follow-up progressed in a manner that was typical for these tumors.
MR Imaging Characteristics
There have been few large studies focused on evaluating imaging characteristics of DIPG at presentation.11,16,20,25–27 Although limited imaging features from a portion of this cohort have been incorporated in 2 prior publications in association with SIOPE (one attempting to validate a DIPG prediction model17 and another looking at predictors of long-term [>2 y] survival),18 the current study comprises the largest single registry cohort assessing imaging features and survival yet reported.
The imaging features of DIPG in this study are generally similar to those described previously, with some notable differences.
Extrapontine extension (90%), thalamic/internal capsule extension (7%), and enhancement (70%) prevalence are similar to that previously described.6,11,12,16,20,25–27 Peripheral, ring-like enhancement was seen in 52% of those with enhancement (35% overall) on the lower end of prior reports (overall 38–50%),6,11,16 which may be due to more stringent criteria used in the current study.
Tumor necrosis has been evaluated previously but has been variably defined, limiting comparisons. Prior studies have referred to presumably necrotic areas as “cyst or necrosis,” 12 “cystic necrosis,” 26 “cyst,” 28,29 or “necrosis” 16,30,31 generally without specific criteria. As detailed in the Supplementary Material (Supplementary 1), we defined necrosis as areas of well-defined, non-enhancing, typically fluid-like signal within the tumor. Because some of the exams did not include post-contrast sequences, peripheral rim-like enhancement was not an absolute criterion for necrosis in this study. As defined, necrotic regions were seen in 44% of tumors (45% of those with contrast administration). Prior literature reports cystic change and/or necrosis in between 20% and 53% of cases, generally similar to the current study. Most regions of necrosis identified in this study (75%) exhibited peripheral, rim-like enhancement when contrast was administered.
Hemorrhage has more rarely been reported in DIPG and performance of SWI or GRE sequences increases sensitivity. Hemorrhage was present in 29% of cases at baseline (50% when evaluating only subjects with GRE or SWI images), similar to prior studies.12,16,29,30,32
Localized areas of relative diffusion restriction were identified visually in most tumors (63%). Due to widely differing techniques and available maps, we were unable to perform quantitative assessments. Given the known correlation of lower baseline apparent diffusion coefficient (ADC) and shortened survival in DIPG,25,33–35 we believed that a visual assessment of diffusion restriction might be useful to describe for future research use and incorporation into the IDIPGR database (Supplementary 1). Similar to other studies, a majority of tumors demonstrated elevated choline, decreased N-acetylaspartate (NAA), and visible lactate peaks on spectroscopy.28,36,37
The presence of distant disease at diagnosis has been infrequently studied in DIPG, and most DIPG patients (as in this cohort) do not have spine imaging at baseline. Overall, 11/357 (3.1%) subjects had distant disease at diagnosis in our cohort (6.8%; 9/133 when assessing only those with spine imaging at baseline). Prior literature regarding baseline prevalence of distant disease is limited. Between 1% and 19% prevalence rate of distant baseline disease has been described,12,16,31,38–40 with larger prevalence in those with spinal imaging at baseline.38 We identified a similar prevalence of distant disease at diagnosis as the SIOPE cohort16 (1.3%, 2.2% in our cohort) and spinal disease (1.9%; 1.7% in our cohort). The assessment of whether non-contiguous parenchymal tumor is metastatic or multifocal and whether there are biologic and survival differences require further study.
It is important to note that all tumors classified as “likely DIPG with unusual features” were indeed considered DIPG and entered into the registry as such. As noted above, hemorrhage, necrosis, and visible diffusion restriction are common in DIPG, and these features alone should not necessarily indicate an alternative diagnosis.
Interobserver Agreement
While the mean concordance between reviewers was good, there was significant variation in agreement depending upon the specific feature assessed. Given these findings, the IDIPGR imaging database will continue to incorporate reviews by 2 neuroradiologists with disagreements in classification adjudicated by consensus opinion.
Correlation of Imaging Features with Overall Survival
Various features of DIPG have previously been correlated with survival in DIPG6,11,18,25,26,32; however, not all studies have found significant associations.12,30 These differences are likely related to number of cases evaluated, imaging criteria and assessment methods, as well as the difficulty in identifying survival predictors in a tumor that has a very short OS. In the present study, extension of tumor beyond the pons, larger tumor size at diagnosis (especially related to larger AP tumor size relative to AP pons size), enhancement, necrosis, visualized regions of diffusion restriction, and distant disease at diagnosis were associated with shorter OS on univariable analysis (with distant disease remaining significant in multivariable analysis).
Extrapontine extension has been previously evaluated by a few investigators with inconsistent definitions11,12,30,31,41 and has not previously correlated with shorter survival when assessed.31,41 Hoffman et al, however, using data from both IDIPGR and SIOPE,18 found that extrapontine extension was found less frequently in long-term survivors (P = 0.04). Both extension of tumor outside of the pons proper or outside the confines of the pons and brachium pontis correlated with shorter OS in our cohort, which may be related to the larger sample size, inclusion of smaller tumors, or more stringent definitions.
Baseline tumor size has been rarely assessed with regard to OS in patients with DIPG. Ahmed et al30 assessing 25 subjects found no correlation of baseline tumor size with OS. Poussaint et al26 assessed tumor volumes and found that larger tumor volume pre-radiotherapy correlated with a longer progression-free survival (PFS) but did not report a relationship to OS. Hoffman et al,18 using data from both IDIPGR and SIOPE, found that long-term (>2 y) survivors had a smaller CC tumor dimension, although there were no significant differences in AP or TR measurement between groups. Larger AP tumor/AP pons measurement ratios (>1) generally occur when the tumor extends laterally or asymmetrically into the brachium pontis and cerebellum, indicating a potentially more advanced stage of tumor extension at baseline (Supplementary 1). Very recently, a study describing decreased survival in DIPG patients with increasing middle cerebellar extension has been published.42 AP tumor/AP pons ratio may be an important prognostic feature and should be assessed in future studies. Steffen-Smith et al43 assessed baseline 1D (transverse) and 2D pons dimensions with OS with shorter survival when 2D pons measurements were above the median. This suggests that larger tumors at baseline have worse prognosis. We used the same method43 but found no statistically significant relationship of 1D or 2D pons size with OS (using Cox proportional hazards regression) or comparing 2D larger than median (1680 mm2) using Kaplan–Meier analysis (data not shown). Discrepancies could potentially relate to numbers of subjects, different measurement methods, and different survival endpoints.
Enhancement has generally been found to correlate with shorter survival, although this is not universal.12,28,30,31 Similar to our analysis, most studies have reported shorter OS in those patients with enhancement.6,11,25,26 Ring enhancement has been noted specifically to be associated with shorter survival by Jansen et al11 in the SIOPE cohort and incorporated into a survival prediction model.
As stated above, necrosis has been variably defined in prior studies limiting comparisons between investigations. In our study the presence of necrosis was significantly associated with shorter OS on univariable analysis. Hoffman et al18 (using combined data from the IDIPGR and SIOPE) found necrosis in a significantly higher proportion of short-term survivors (42%) than long-term survivors (26%). Other investigators describing necrosis in DIPG have either not assessed its relationship to survival26,29 or found it not significant.12,28,30,31
Quantitative assessment of diffusion characteristics of DIPG has been reported, with most reporting some relationship to survival. We found that those tumors with visibly restricted diffusion had shorter OS on univariable analysis. While techniques utilized are varied (region-of-interest, histogram analysis), several authors have reported worse survival (OS and PFS) with lower intratumoral baseline ADC values,25,33–35,44 consistent with our visual assessment observations.
Careful quantitative studies have shown variable relationships of baseline perfusion imaging with survival.26,36,45 Detailed quantitative spectroscopy studies have suggested that those tumors with higher choline/NAA ratios28,36,37 and lactate visualization28 have shorter survival. Perfusion imaging and spectroscopy could only be evaluated in a subjective fashion in a small number of subjects in this study, and no statistically significant relationship between perfusion status or MR spectroscopy findings and survival was noted. This is not surprising considering the small numbers, non-quantitative assessment, and variable techniques used in the submitted registry imaging data.
Prognostic implications of distant disease at diagnosis in DIPG have been rarely assessed. This study confirms that the presence of distant disease at diagnosis, while infrequent, is a strong predictor of poor OS. A full understanding of the prevalence of distant disease in DIPG is limited by the lack of routine performance of baseline spine imaging in this group.38,39 While spinal dissemination is rare, consideration should be given to performing spinal imaging at baseline in these patients. Most prior studies have focused on disseminated disease during treatment and relapse,38–40 with presence of disseminated disease (regardless of local disease status) typically associated with poor prognosis.38
Correlation with Histone Status
Very few studies have evaluated imaging in DIPG and histone mutation status. Our study is the first using a large number of registry-defined imaging features to assess differences in imaging appearance between H3 mutated and WT, as well as between H3.3 and H3.1 mutated DIPGs. Although our numbers are small, we did not find a statistically significant relationship between any registry imaging feature and histone status (H3 vs WT or H3.3 vs H3.1). Castel et al6 found a higher prevalence of necrosis, edema (evidenced by infiltrative T2 signal within the pons, so-called T2-stripes), ring enhancement, and more restricted diffusion (by histogram analysis) in H3.1 versus H3.3 tumors. We also found infiltrative T2 signal (T2-stripes) more prevalent in H3.1 tumors in agreement with Castel et al; however, we did not find any other statistically significant difference between these 2 groups. The trends in our data (more common enhancement and necrosis in H3.1 tumors) are generally consistent with those of Castel et al, with the smaller number of subjects with known histone status in our population a possible explanation. Aboian et al8 evaluated 33 patients with diffuse midline gliomas (only 14 of pontine origin) and found diverse imaging appearances without distinguishing features between histone H3 and WT diffuse gliomas. The lack of strong correlation with visually identified imaging features and histone mutation status is not surprising, given the poor correlation between histopathology (more strongly predictive of imaging appearance) and histone mutation status.18 Inherent limitations in visual analysis of imaging studies point out the need for more advanced data-driven approaches, including machine learning, in this patient population.
Surprisingly, we found no correlation between histone status and OS. Previous reports have generally shown a shorter OS in patients with H3.3 mutation versus WT or H3.1,6 suggesting that H3.3 mutated tumors are more aggressive. Hoffman et al,18 evaluating 181 subjects in which genomic data were available (combined data from the IDIPGR and SIOPE), documented fewer long-term survivors in those with H3.3 versus H3.1 mutations. They, however, also found no difference in the prevalence of short-term survivors between H3 and WT tumors. The reasons for the lack of correlation between survival and histone status in our study are uncertain but may relate to smaller numbers of subjects evaluated and the use of different techniques than other studies assessing this relationship. There does seem to be a discrepancy between imaging features related to survival and those related to histone status6 that has not been fully explained or investigated. In our study the presence of enhancement, necrosis, and diffusion restriction are features related to shorter OS. In the study by Castel et al (and supported by trends in our data), these are features that are more prevalent in H3.1 mutated tumors (compared with H3.3 tumors), which exhibit longer OS in most studies that have assessed this feature. Reasons for this discrepancy are unclear, but may be related to an imaging and histopathology independent association of the H3.3 mutation with survival. Although the primary objective of this study was to correlate DIPG imaging features with OS, multivariable analysis found that the use of systemic chemotherapy led to improved OS, as previously reported by Hoffman et al in a combined report from the IDIPGR and SIOPE registries17 and by others.46–48 However, the inherent limitations of registry data including enrollment, reporting, and survival bias lead us to interpret this finding with caution. The general consensus remains that systemic therapy provides little survival benefit for patient with DIPG.48,49 Limitations to this study are discussed in the Supplementary Material (Supplementary 4).
Conclusions
Baseline imaging features were assessed in 357 subjects in the IDIPGR using standardized imaging features which will serve as a resource for ongoing and future collaborative research projects. Nearly 10% of studies submitted to the registry with a local diagnosis of DIPG were categorized as non-DIPG by study reviewers highlighting the need for imaging confirmation by central review for prospective trials. Multiple imaging features correlate with OS on univariable analysis, helping validate the utility of the imaging classification scheme. Distant disease at diagnosis portends a poor prognosis. There was no statistically significant correlation of imaging features with histone mutation status, although numbers are small and evaluation exploratory. Further in-depth research in genomic-radiologic classifications is needed, in part using advanced imaging techniques such as textural analysis and machine learning to probe for additional correlations.
Funding
Supporting foundations include: The Cure Starts Now Foundation, Julian Boivin Courage for Cures Foundation, Hope for Caroline Foundation, The Cure Starts Now Australia, Aidan’s Avengers, Austin Strong, Brooke Healey Foundation, ChadTough Foundation, Cure Brain Cancer, Grant’s Ginormous Gift, Jeffrey Thomas Hayden Foundation, Love Chloe Foundation, Musella Foundation, Operation Grace White, Pray Hope Believe Foundation, Reflections of Grace, Ryan’s Hope, Storm the Heavens Fund, Benny’s World, Julia Barbara Foundation, Lauren’s Fight for Cure, Lily Larue Foundation, The Isabella and Marcus Foundation, Canadian Children’s Brain Cancer Foundation, Danni Kemp Cancer Support Fund, Smile for Brooklyn, The Gold Hope Project, Abbie’s Army, Michael Mosier Defeat DIPG Foundation, Soar With Grace Foundation, The Jones Family Foundation, Smiles for Sophie Foundation, A Cure from Caleb Society, Wayland Villars DIPG Foundation, American Childhood Cancer Organization, Juliana Rose Donnelly Trust, Sheila Jones & Friends, The Ellie Kavalieros DIPG Research Fund, Voices Against Brain Cancer, and The DIPG Collaborative as well as the Kyler Strong Foundation and Keris Kares. We also acknowledge the support of the Child Health Research Institute, Stanford University.
Conflict of interest statement. None declared.
Authorship statement. Conception and design: JLL, BVJ, MF, JR, AS, BC, AL, MDS, R Doughman, R Drissi, CF. Acquisition of data: JLL, BVJ, MF, JR, AS, BC, AL, MDS, R Doughman, R Drissi, CF, DZ, JM, JH, SW, MD, PF, NG, HD, RP, KW, SL, SG, UB, CH. Analysis and interpretation of data: JLL, BVJ, MF, JR, AS, BC, AL, MDS, R Doughman, R Drissi, CF. Drafting or revising critically for important intellectual content: All authors. Final approval of the version to be published: All authors.
Supplementary Material
Acknowledgments
Please see: https://dipgregistry.org/about/supporters/, and Supplementary 5.
References
- 1. Green AL, Kieran MW. Pediatric brainstem gliomas: new understanding leads to potential new treatments for two very different tumors. Curr Oncol Rep. 2015;17(3):436. [DOI] [PubMed] [Google Scholar]
- 2. Fischbein NJ, Prados MD, Wara W, Russo C, Edwards MS, Barkovich AJ. Radiologic classification of brain stem tumors: correlation of magnetic resonance imaging appearance with clinical outcome. Pediatr Neurosurg. 1996;24(1):9–23. [DOI] [PubMed] [Google Scholar]
- 3. Khuong-Quang DA, Buczkowicz P, et al. K27M mutationin histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol. 2012;2012(3):439–447. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012;482(7384):226–231. [DOI] [PubMed] [Google Scholar]
- 5. Wu G, Broniscer A, McEachron TA, et al. ; St Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet. 2012;44(3):251–253. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Castel D, Philippe C, Calmon R, et al. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol. 2015;130(6):815–827. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–820. [DOI] [PubMed] [Google Scholar]
- 8. Aboian MS, Solomon DA, Felton E, et al. Imaging characteristics of pediatric diffuse midline gliomas with histone H3 K27M mutation. AJNR Am J Neuroradiol. 2017;38(4):795–800. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Tisnado J, Young R, Peck KK, Haque S. Conventional and advanced imaging of diffuse intrinsic pontine glioma. J Child Neurol. 2016;31(12):1386–1393. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Choux M, Lena G, Do L. Brainstem tumors. In: Choux M, DC, Hockley A, eds. Pediatric Neurosurgery. New York, NY: Churchill Livingstone; 2000:471–491. [Google Scholar]
- 11. Jansen MH, Veldhuijzen van Zanten SE, Sanchez Aliaga E, et al. Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria. Neuro Oncol. 2015;17(1):160–166. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Hargrave D, Chuang N, Bouffet E. Conventional MRI cannot predict survival in childhood diffuse intrinsic pontine glioma. J Neurooncol. 2008;86(3):313–319. [DOI] [PubMed] [Google Scholar]
- 13. Hankinson TC, Campagna EJ, Foreman NK, Handler MH. Interpretation of magnetic resonance images in diffuse intrinsic pontine glioma: a survey of pediatric neurosurgeons. J Neurosurg Pediatr. 2011;8(1):97–102. [DOI] [PubMed] [Google Scholar]
- 14. Lesniak MS, Klem JM, Weingart J, Carson BS Sr. Surgical outcome following resection of contrast-enhanced pediatric brainstem gliomas. Pediatr Neurosurg. 2003;39(6):314–322. [DOI] [PubMed] [Google Scholar]
- 15. Baugh J, Bartels U, Leach J, et al. The international diffuse intrinsic pontine glioma registry: an infrastructure to accelerate collaborative research for an orphan disease. J Neurooncol. 2017;132(2):323–331. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Veldhuijzen van Zanten SEM, Baugh J, Chaney B, et al. ; members of the SIOPE DIPG Network Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease. J Neurooncol. 2017;132(2):255–266. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Veldhuijzen van Zanten SEM, Lane A, Heymans MW, et al. External validation of the diffuse intrinsic pontine glioma survival prediction model: a collaborative report from the International DIPG Registry and the SIOPE DIPG Registry. J Neurooncol. 2017;134(1):231–240. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Hoffman LM, Veldhuijzen van Zanten SEM, Colditz N, et al. Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of diffuse intrinsic pontine glioma (DIPG): a collaborative report from the International and European Society for Pediatric Oncology DIPG Registries. J Clin Oncol. 2018;36(19):1963–1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Clerk-Lamalice O, Reddick WE, Li X, et al. MRI evaluation of non-necrotic T2-hyperintense foci in pediatric diffuse intrinsic pontine glioma. AJNR Am J Neuroradiol. 2016;37(10):1930–1937. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Barkovich AJ, Krischer J, Kun LE, et al. Brain stem gliomas: a classification system based on magnetic resonance imaging. Pediatr Neurosurg. 1990;16(2):73–83. [DOI] [PubMed] [Google Scholar]
- 21. Zagzag D, Miller DC, Knopp E, et al. Primitive neuroectodermal tumors of the brainstem: investigation of seven cases. Pediatrics. 2000;106(5):1045–1053. [DOI] [PubMed] [Google Scholar]
- 22. Sufit A, Donson AM, Birks DK, et al. Diffuse intrinsic pontine tumors: a study of primitive neuroectodermal tumors versus the more common diffuse intrinsic pontine gliomas. J Neurosurg Pediatr. 2012;10(2):81–88. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Löbel U, Sedlacik J, Reddick WE, et al. Quantitative diffusion-weighted and dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging analysis of T2 hypointense lesion components in pediatric diffuse intrinsic pontine glioma. AJNR Am J Neuroradiol. 2011;32(2):315–322. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Caretti V, Bugiani M, Freret M, et al. Subventricular spread of diffuse intrinsic pontine glioma. Acta Neuropathol. 2014;128(4):605–607. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Poussaint TY, Vajapeyam S, Ricci KI, et al. Apparent diffusion coefficient histogram metrics correlate with survival in diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium. Neuro Oncol. 2016;18(5):725–734. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Poussaint TY, Kocak M, Vajapeyam S, et al. MRI as a central component of clinical trials analysis in brainstem glioma: a report from the Pediatric Brain Tumor Consortium (PBTC). Neuro Oncol. 2011;13(4):417–427. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Conway AE, Reddick WE, Li Y, et al. “Occult” post-contrast signal enhancement in pediatric diffuse intrinsic pontine glioma is the MRI marker of angiogenesis? Neuroradiology. 2014;56(5):405–412. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Yamasaki F, Kurisu K, Kajiwara Y, et al. Magnetic resonance spectroscopic detection of lactate is predictive of a poor prognosis in patients with diffuse intrinsic pontine glioma. Neuro Oncol. 2011;13(7):791–801. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Farmer JP, Montes JL, Freeman CR, Meagher-Villemure K, Bond MC, O’Gorman AM. Brainstem gliomas. A 10-year institutional review. Pediatr Neurosurg. 2001;34(4):206–214. [DOI] [PubMed] [Google Scholar]
- 30. Ahmed MA, Eldebawy E, Ahmed S, Refaat A, Attala E, Shafik H, Ezzat S, Zaghloul M. Can conventional magnetic resonance imaging predict survival in pediatric diffuse intrinsic pontine glioma? A single institution experience. Egypt J Radiol Nucl Med. 2013;44:871–878. [Google Scholar]
- 31. Kornreich L, Schwarz M, Karmazyn B, et al. Role of MRI in the management of children with diffuse pontine tumors: a study of 15 patients and review of the literature. Pediatr Radiol. 2005;35(9):872–879. [DOI] [PubMed] [Google Scholar]
- 32. Löbel U, Sedlacik J, Sabin ND, et al. Three-dimensional susceptibility-weighted imaging and two-dimensional T2*-weighted gradient-echo imaging of intratumoral hemorrhages in pediatric diffuse intrinsic pontine glioma. Neuroradiology. 2010;52(12):1167–1177. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Lober RM, Cho YJ, Tang Y, et al. Diffusion-weighted MRI derived apparent diffusion coefficient identifies prognostically distinct subgroups of pediatric diffuse intrinsic pontine glioma. J Neurooncol. 2014;117(1):175–182. [DOI] [PubMed] [Google Scholar]
- 34. Chen HJ, Panigrahy A, Dhall G, Finlay JL, Nelson MD Jr, Blüml S. Apparent diffusion and fractional anisotropy of diffuse intrinsic brain stem gliomas. AJNR Am J Neuroradiol. 2010;31(10):1879–1885. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Zukotynski KA, Vajapeyam S, Fahey FH, et al. Correlation of 18F-FDG PET and MRI apparent diffusion coefficient histogram metrics with survival in diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium. J Nucl Med. 2017;58(8):1264–1269. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Hipp SJ, Steffen-Smith E, Hammoud D, Shih JH, Bent R, Warren KE. Predicting outcome of children with diffuse intrinsic pontine gliomas using multiparametric imaging. Neuro Oncol. 2011;13(8): 904–909. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. Steffen-Smith EA, Shih JH, Hipp SJ, Bent R, Warren KE. Proton magnetic resonance spectroscopy predicts survival in children with diffuse intrinsic pontine glioma. J Neurooncol. 2011;105(2):365–373. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38. Sethi R, Allen J, Donahue B, et al. Prospective neuraxis MRI surveillance reveals a high risk of leptomeningeal dissemination in diffuse intrinsic pontine glioma. J Neurooncol. 2011;102(1):121–127. [DOI] [PubMed] [Google Scholar]
- 39. Wagner S, Benesch M, Berthold F, et al. Secondary dissemination in children with high-grade malignant gliomas and diffuse intrinsic pontine gliomas. Br J Cancer. 2006;95(8):991–997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40. Gururangan S, McLaughlin CA, Brashears J, et al. Incidence and patterns of neuraxis metastases in children with diffuse pontine glioma. J Neurooncol. 2006;77(2):207–212. [DOI] [PubMed] [Google Scholar]
- 41. Moghrabi A, Kerby T, Tien RD, Friedman HS. Prognostic value of contrast-enhanced magnetic resonance imaging in brainstem gliomas. Pediatr Neurosurg. 1995;23(6):293–298. [DOI] [PubMed] [Google Scholar]
- 42. Makepeace L, Scoggins M, Mitrea B, et al. MRI patterns of extrapontine lesion extension in diffuse intrinsic pontine gliomas. AJNR Am J Neuroradiol. 2020;41(2):323–330. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Steffen-Smith EA, Baker EH, Venzon D, Shandilya S, Bent RS, Warren KE. Measurements of the pons as a biomarker of progression for pediatric DIPG. J Neurooncol. 2014;116(1):127–133. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44. Aboian MS, Tong E, Solomon DA, et al. Diffusion characteristics of pediatric diffuse midline gliomas with histone H3-K27M mutation using apparent diffusion coefficient histogram analysis. AJNR Am J Neuroradiol. 2019;40(11):1804–1810. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45. Sedlacik J, Winchell A, Kocak M, Loeffler RB, Broniscer A, Hillenbrand CM. MR imaging assessment of tumor perfusion and 3D segmented volume at baseline, during treatment, and at tumor progression in children with newly diagnosed diffuse intrinsic pontine glioma. AJNR Am J Neuroradiol. 2013;34(7):1450–1455. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46. Wagner S, Warmuth-Metz M, Emser A, et al. Treatment options in childhood pontine gliomas. J Neurooncol. 2006;79(3):281–287. [DOI] [PubMed] [Google Scholar]
- 47. Gokce-Samar Z, Beuriat PA, Faure-Conter C, et al. Pre-radiation chemotherapy improves survival in pediatric diffuse intrinsic pontine gliomas. Childs Nerv Syst. 2016;32(8):1415–1423. [DOI] [PubMed] [Google Scholar]
- 48. Hargrave D, Bartels U, Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol. 2006;7(3):241–248. [DOI] [PubMed] [Google Scholar]
- 49. Warren KE. Diffuse intrinsic pontine glioma: poised for progress. Front Oncol. 2012;2:205. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.